Alex Biese

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

Researchers have found that interventions can make breast cancer survivors nearly 1.5 times more likely to continue with important post-surgical hormonal therapy.

Geoff Grubbs, who was diagnosed with chronic lymphocytic leukemia in 2009, has undergone five lines of treatment and participated in two clinical trials.

The Food and Drug Administration has approved the combination of Lonsurf and Avastin for patients with metastatic colorectal cancer previously treated with chemotherapies, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy.

Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.

A study of patients with cancer found that more than a quarter were using cannabis, and those who did so were likely to report having experienced more severe symptoms.

A recent study documented the benefits of maintaining normal vitamin D levels for patients with inoperable, locally advanced or metastatic melanoma receiving anti-PD-1 immunotherapy.

Christina McAmis’ cancer journey began when she found a lump while breastfeeding. The attorney and mother of three tells the “Cancer Horizons” podcast what the last nine years have been like for her and her family.

The Food and Drug Administration is reportedly expediting the review of Ambrx’s treatment for patients with metastatic, castration-resistant prostate cancer that has displayed promising early trial results.

Receiving a diagnosis of breast cancer and radiation treatment were both associated with increased rates of biological aging among patients who participated in a recent study.

Advancements have been made over the last decade in the use of immunotherapy for the treatment of skin cancers including melanoma, squamous cell carcinoma and Merkel cell carcinoma.

Patients with MPNs can potentially experience long asymptomatic periods, and it’s up to patients and providers to remain vigilant as they monitor and manage symptoms.

Having a strong connection with their care team can be crucial for the well-being of LGBTQ+ patients with cancer, as a colorectal cancer survivor and surgeon from City of Hope told CURE®.

A recent study has determined that Xospata plus chemo is safe for the treatment of relapsed/refractory acute myeloid leukemia with an FLT3 mutation.

A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma.

Darcie Green, executive director of service and advocacy organization Latinas Contra Cancer, tells the CURE® “Cancer Horizon” podcast about how its work has broadened over the last 20 years.

When paired with the chemotherapy combination doxorubicin, vinblastine and dacarbazine, Keytruda resulted in 100% overall survival in the findings from a new study of adult patients with classic Hodgkin lymphoma.

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer.

Immigrant and foreign-born cancer survivors experience several disparities that suggest barriers to care and “may portent worse health outcomes in cancer survivorship,” according to researchers.

William S. Laird, author of the unflinching memoir “Not Me, Cancer,” speaks with CURE’s “Cancer Horizons” podcast about the decision to share his story and the importance of perseverance.

Kim Stuck, who was diagnosed with breast cancer last year, says she "couldn’t even imagine not having cannabis during that time."

The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”

The NALIRIFOX regimen of Onivyde plus 5-fluorouracil/leucovorin and oxaliplatin has been shown to have survival and disease progression benefits for patients with pancreatic cancer in a clinical trial setting.

Factors including race, insurance and treatment history have been associated with increased cardiovascular disease, risk factors and mortality among cancer survivors, including those with a history of pediatric cancer, according to recent research.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

A significant majority of patients with early-stage classical Hodgkin lymphoma demonstrated a complete response to treatment with Adcetris, Opdivo and chemotherapy.

Mindfulness meditation can make a big difference in the treatment experience of patients.

For patients who don’t speak English, there can be additional obstacles during their cancer journey. Resources, family, care providers, fellow patients and the law are on their side.

Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.